S-(1,2,3,4,4-pentachloro-1,3-butadienyl)glutathione: nephrotoxin; RN given for (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3035006 |
| MeSH ID | M0144159 |
| Synonym |
|---|
| s-(1,2,3,4,4-pentachloro-1,3-butadienyl)glutathione |
| n-(n-l-gamma-glutamyl-s-(1,2,3,4,4-pentachloro-1,3-butadienyl)-l-cysteinyl)glycine |
| 1-(glutathion-s-yl)-1,2,3,4,4-pentachloro-1,3-butadiene |
| glycine, n-(n-l-gamma-glutamyl-s-(1,2,3,4,4-pentachloro-1,3-butadienyl)-l-cysteinyl)- |
| pcbg |
| ccris 1522 |
| 89021-88-5 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In contrast apical treatment with PCBD-NAC was only toxic at high concentrations (greater than 850 microM), and this effect could hardly be inhibited by AOAA." | ( Differential toxicity as a result of apical and basolateral treatment of LLC-PK1 monolayers with S-(1,2,3,4,4-pentachlorobutadienyl)glutathione and N-acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine. Mertens, JJ; Spenkelink, B; Temmink, JH; van Bladeren, PJ; van Doorn, WJ; Weijnen, JG, 1988) | 0.27 |
| " HCBD was about four times more toxic to female rats than males." | ( Nephrotoxicity of hexachlorobutadiene and its glutathione-derived conjugates. Ishmael, J; Lock, EA, 1986) | 0.27 |
| " Toxic doses of PCBG also resulted in the depletion of cellular thiols." | ( The mechanism of pentachlorobutadienyl-glutathione nephrotoxicity studied with isolated rat renal epithelial cells. Gerdes, RG; Jones, TW; Ormstad, K; Orrenius, S; Thor, H; Wallin, A, 1986) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The cytotoxicity of PCBG displayed a very steep dose-response relationship; at 10 microM PCBG no toxicity was observed whereas 25, 50, and 100 microM PCBG all resulted in a similar degree of toxicity." | ( The mechanism of pentachlorobutadienyl-glutathione nephrotoxicity studied with isolated rat renal epithelial cells. Gerdes, RG; Jones, TW; Ormstad, K; Orrenius, S; Thor, H; Wallin, A, 1986) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||